Tempest Capital Expenditures vs Begin Period Cash Flow Analysis

TPST Stock

USD 0.95 0.04 4.04%

Tempest Therapeutics financial indicator trend analysis is much more than just breaking down Tempest Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tempest Therapeutics is a good investment. Please check the relationship between Tempest Therapeutics Capital Expenditures and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Capital Expenditures vs Begin Period Cash Flow

Capital Expenditures vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tempest Therapeutics Capital Expenditures account and Begin Period Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Tempest Therapeutics' Capital Expenditures and Begin Period Cash Flow is -0.22. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Tempest Therapeutics, assuming nothing else is changed. The correlation between historical values of Tempest Therapeutics' Capital Expenditures and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Tempest Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Capital Expenditures i.e., Tempest Therapeutics' Capital Expenditures and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.22

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Tempest Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Tempest Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Tempest Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tempest Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.Selling General Administrative is likely to gain to about 15.4 M in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 1.1 M in 2025.

Tempest Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Net Debt	Retained Earnings	Cash	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Total Current Assets	Other Current Liab	Total Stockholder Equity	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Common Stock	Current Deferred Revenue	Short Long Term Debt Total	Net Receivables	Short Term Debt
Total Assets		0.73	-0.66	-0.72	0.62	0.75	-0.34	-0.17	0.99	0.71	0.78	0.33	0.77	0.31	0.59	0.92	-0.02	0.62	0.29	0.79	0.32	0.56	-0.06	-0.04	0.13	0.01
Total Current Liabilities	0.73		-0.55	-0.58	0.71	0.55	-0.17	0.06	0.71	0.93	0.43	0.37	0.31	0.35	0.4	0.52	0.21	0.14	0.75	0.6	0.4	0.15	-0.12	0.4	0.56	0.34
Net Debt	-0.66	-0.55		0.49	-0.88	-0.21	0.2	0.07	-0.69	-0.59	-0.5	0.03	-0.41	0.13	-0.45	-0.64	0.22	-0.08	-0.4	-0.4	0.03	-0.09	-0.13	0.16	-0.15	0.12
Retained Earnings	-0.72	-0.58	0.49		-0.54	-0.81	0.17	0.03	-0.7	-0.47	-0.48	-0.41	-0.48	-0.4	-0.89	-0.6	-0.17	-0.34	-0.11	-0.84	-0.4	-0.68	0.11	-0.13	0.11	-0.19
Cash	0.62	0.71	-0.88	-0.54		0.23	-0.09	0.08	0.6	0.61	0.34	0.37	0.15	0.27	0.51	0.44	0.23	-0.18	0.5	0.41	0.38	-0.07	-0.12	0.33	0.18	0.34
Common Stock Total Equity	0.75	0.55	-0.21	-0.81	0.23		-0.05	0.08	0.72	0.46	0.4	0.35	0.59	0.4	0.59	0.59	0.09	0.58	0.06	0.71	0.34	0.76	-0.12	0.05	-0.02	0.09
Non Current Liabilities Total	-0.34	-0.17	0.2	0.17	-0.09	-0.05		0.97	-0.36	-0.25	-0.81	0.11	-0.36	0.1	-0.33	-0.45	0.12	-0.38	-0.03	-0.61	0.07	-0.28	-0.05	0.2	-0.11	0.16
Total Liab	-0.17	0.06	0.07	0.03	0.08	0.08	0.97		-0.2	-0.03	-0.71	0.2	-0.29	0.18	-0.24	-0.34	0.18	-0.35	0.15	-0.48	0.16	-0.25	-0.07	0.3	0.03	0.24
Total Current Assets	0.99	0.71	-0.69	-0.7	0.6	0.72	-0.36	-0.2		0.72	0.8	0.23	0.8	0.21	0.56	0.94	-0.11	0.64	0.3	0.76	0.23	0.55	-0.04	-0.14	0.16	-0.07
Other Current Liab	0.71	0.93	-0.59	-0.47	0.61	0.46	-0.25	-0.03	0.72		0.51	0.1	0.4	0.08	0.25	0.6	-0.06	0.24	0.81	0.53	0.12	0.12	-0.03	0.12	0.68	0.08
Total Stockholder Equity	0.78	0.43	-0.5	-0.48	0.34	0.4	-0.81	-0.71	0.8	0.51		0.04	0.73	0.03	0.49	0.89	-0.22	0.71	0.13	0.82	0.05	0.55	0.09	-0.28	0.11	-0.24
Property Plant And Equipment Net	0.33	0.37	0.03	-0.41	0.37	0.35	0.11	0.2	0.23	0.1	0.04		-0.04	0.98	0.43	0.07	0.89	-0.13	-0.06	0.33	1.0	0.06	-0.6	0.78	-0.25	0.82
Accounts Payable	0.77	0.31	-0.41	-0.48	0.15	0.59	-0.36	-0.29	0.8	0.4	0.73	-0.04		-0.04	0.45	0.86	-0.41	0.84	-0.02	0.6	-0.07	0.63	0.17	-0.5	-0.05	-0.45
Non Current Assets Total	0.31	0.35	0.13	-0.4	0.27	0.4	0.1	0.18	0.21	0.08	0.03	0.98	-0.04		0.38	0.05	0.88	-0.07	-0.08	0.35	0.98	0.12	-0.6	0.77	-0.25	0.82
Non Currrent Assets Other	0.59	0.4	-0.45	-0.89	0.51	0.59	-0.33	-0.24	0.56	0.25	0.49	0.43	0.45	0.38		0.49	0.24	0.23	-0.07	0.78	0.42	0.56	-0.15	0.14	-0.27	0.2
Cash And Short Term Investments	0.92	0.52	-0.64	-0.6	0.44	0.59	-0.45	-0.34	0.94	0.6	0.89	0.07	0.86	0.05	0.49		-0.3	0.78	0.17	0.76	0.05	0.63	0.13	-0.34	0.09	-0.29
Common Stock Shares Outstanding	-0.02	0.21	0.22	-0.17	0.23	0.09	0.12	0.18	-0.11	-0.06	-0.22	0.89	-0.41	0.88	0.24	-0.3		-0.44	-0.08	0.09	0.91	-0.15	-0.73	0.86	-0.22	0.96
Short Term Investments	0.62	0.14	-0.08	-0.34	-0.18	0.58	-0.38	-0.35	0.64	0.24	0.71	-0.13	0.84	-0.07	0.23	0.78	-0.44		-0.15	0.58	-0.15	0.79	0.25	-0.52	-0.03	-0.51
Other Current Assets	0.29	0.75	-0.4	-0.11	0.5	0.06	-0.03	0.15	0.3	0.81	0.13	-0.06	-0.02	-0.08	-0.07	0.17	-0.08	-0.15		0.15	-0.03	-0.32	0.13	0.28	0.91	0.11
Other Stockholder Equity	0.79	0.6	-0.4	-0.84	0.41	0.71	-0.61	-0.48	0.76	0.53	0.82	0.33	0.6	0.35	0.78	0.76	0.09	0.58	0.15		0.33	0.72	0.0	0.07	0.05	0.07
Property Plant And Equipment Gross	0.32	0.4	0.03	-0.4	0.38	0.34	0.07	0.16	0.23	0.12	0.05	1.0	-0.07	0.98	0.42	0.05	0.91	-0.15	-0.03	0.33		0.04	-0.63	0.8	-0.21	0.85
Common Stock	0.56	0.15	-0.09	-0.68	-0.07	0.76	-0.28	-0.25	0.55	0.12	0.55	0.06	0.63	0.12	0.56	0.63	-0.15	0.79	-0.32	0.72	0.04		0.08	-0.32	-0.3	-0.2
Current Deferred Revenue	-0.06	-0.12	-0.13	0.11	-0.12	-0.12	-0.05	-0.07	-0.04	-0.03	0.09	-0.6	0.17	-0.6	-0.15	0.13	-0.73	0.25	0.13	0.0	-0.63	0.08		-0.38	0.21	-0.73
Short Long Term Debt Total	-0.04	0.4	0.16	-0.13	0.33	0.05	0.2	0.3	-0.14	0.12	-0.28	0.78	-0.5	0.77	0.14	-0.34	0.86	-0.52	0.28	0.07	0.8	-0.32	-0.38		0.13	0.86
Net Receivables	0.13	0.56	-0.15	0.11	0.18	-0.02	-0.11	0.03	0.16	0.68	0.11	-0.25	-0.05	-0.25	-0.27	0.09	-0.22	-0.03	0.91	0.05	-0.21	-0.3	0.21	0.13		-0.07
Short Term Debt	0.01	0.34	0.12	-0.19	0.34	0.09	0.16	0.24	-0.07	0.08	-0.24	0.82	-0.45	0.82	0.2	-0.29	0.96	-0.51	0.11	0.07	0.85	-0.2	-0.73	0.86	-0.07

Click cells to compare fundamentals

Tempest Therapeutics Account Relationship Matchups

Tempest Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	22.9M	73.2M	46.1M	51.6M	59.3M	70.9M
Total Current Liabilities	3.2M	20.0M	7.3M	9.4M	10.8M	9.6M
Net Debt	(16.4M)	(33.3M)	(9.1M)	(18.6M)	(16.7M)	(17.5M)
Retained Earnings	(71.8M)	(100.1M)	(135.8M)	(165.3M)	(148.7M)	(156.2M)
Cash	18.8M	51.8M	31.2M	39.2M	45.1M	35.9M
Liabilities And Stockholders Equity	22.9M	73.2M	46.1M	51.6M	59.3M	70.9M
Non Current Liabilities Total	88.4M	17.1M	20.7M	15.4M	17.7M	13.0M
Total Liab	91.7M	37.1M	28.0M	24.8M	28.6M	22.6M
Total Current Assets	19.8M	69.0M	33.0M	40.4M	46.4M	65.6M
Other Current Liab	1.4M	16.2M	3.3M	3.3M	3.8M	7.2M
Total Stockholder Equity	(68.8M)	36.1M	18.1M	26.8M	24.1M	37.9M
Property Plant And Equipment Net	3.0M	4.2M	12.7M	10.8M	12.4M	13.0M
Accounts Payable	1.1M	991K	1.1M	845K	760.5K	1.4M
Non Current Assets Total	3.0M	4.3M	13.1M	11.2M	12.9M	13.6M
Non Currrent Assets Other	51K	111K	429K	448K	515.2K	405.2K
Cash And Short Term Investments	18.8M	51.8M	31.2M	39.2M	35.3M	48.4M
Common Stock Shares Outstanding	31.2K	3.8M	11.5M	15.4M	17.7M	18.6M
Other Current Assets	745K	17.1M	1.4M	1.1M	1.3M	1.2M
Other Stockholder Equity	(170.9M)	136.2M	153.9M	192.0M	172.8M	130.6M
Property Plant And Equipment Gross	2.2M	5.0M	12.7M	11.8M	13.6M	14.3M
Common Stock	15K	7K	11K	22K	19.8K	16.1K
Short Long Term Debt Total	2.4M	18.5M	22.1M	20.7M	23.8M	12.6M
Net Receivables	1.3M	260K	15M	450K	517.5K	491.6K
Short Term Debt	712K	2.9M	2.8M	5.2M	6.0M	6.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC